Home » Natural Sciences » Faculty/Staff
Shelley Riley
Assistant Professor
Education
- Ph.D
Pharmaceutical Chemistry, University of Kansas
- M.S.
Pharmaceutical Chemistry, University of Kansas
- B.S.
Chemistry, Northwest Missouri State University
Courses Taught
-
24-114/115 General
Chemistry I and Lab
-
24-117 General
Chemistry II Lab
-
24-135 Laboratory
Safety
-
24-499 Special
Investigations in Chemistry
-
24-522/523 Instrumental
Analysis and Lab
-
24-592 Chemistry
Seminar
Academic Interests
- Elemental Analysis
- Thermal Analysis of Solids
- Separation Methods and Spectroscopy Applications
Scholarly Activity
- Dr. Riley's research interests are in Solid State Characterization
of Pharmaceuticals and Formulation/Characterization
of Nanosuspensions for Oral Drug Delivery.
Selected Publications/Patents
- Rabel Riley, S.R.; Vickery, R.D.; Nemeth, G.A.;
Haas, M.J.; Kasprzak, D.J. Maurin, M.B. Thermal Decomposition of Matrix
Metalloproteinase Inhibitors; Evidence of a Solid State
Dimerization. J. Pharm. Biomed. Anal. 2011, 54, 324-330.
- Murphy, D. and Rabel, S. Thermal
Analysis and Calorimetric Methods for Characterization of New Crystalline
Forms. In: Preformulation
in Solid Dosage Form Development;
Adeyeye, C., Brittain, H., Eds.; Informa Healthcare USA, Inc.; Mew York,
NY, 2008, p 279 - 322.
- Method
for screening of solid dispersion formulations of low-solubility
compounds-Miniaturization and automation of solvent casting and
dissolution
testing. Anant Shanbhag, Shelley Rabel, Ewa Nauka,
Gemma Casadevall, Padmaja Shivanand, Gary Eichenbaum, Paul Mansky.
International Journal of Pharmaceutics, Volume 351, Issues
1-2, 209-218. March 3, 2008.
- P. J. Gilligan, S. R. Rabel Riley, P.A. Meenan. Salt and Crystalline Form Thereof of a
Corticotrophin Releasing Factor Receptor Antagonist. U.S. Patent 7153961 B2, Dec. 26, 2006
- L. Radesca, James R. Moore, S. R. Rabel, and M. B. Maurin, Crystalline Efavirenz. U.S. Patent 6673372, Jan. 6, 2004.
- Polymorphism of Roxifiban. Michael B. Maurin, Rodney D. Vickery, Shelley
R. Rabel, Susan M. Rowe, J. Gerry Everlof, Gregory A. Nemeth, G. Creston
Campbell, and C.M. Foris. Journal of Pharmaceutical Sciences, Vol 19, No. 12,
December 2002.
- Degradation
of a fluoropyridinyl drug in capsule formulation: degradant identification, proposed
degradation mechanism, and formulation optimization. J. G. Chen, D.A. Markovitz, A. Y. Yang, S.
Rabel, J. Pang, O. Dolinsky, L.S. Wu, M. Alasandro. Pharmaceutical Development Technology 2000,
pp. 561-570.
- Characterization
of the Solution Stability and Degradation Products of the Novel
Neurotransmitter Release Enhancer
10,10,-Bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone, (DMP 543). Shelley
R. Rabel, Mirwais K. Shinwari, Gregory A. Nemeth, Karl F. Blom and Michael B.
Maurin. Drug Stability, vol. 1 (No. 4),
1997, pp 224-230.
- Determination
of the pKa and pH-Solubility Behavior of an Ionizable
Cyclic Carbamate,
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-Dihydro-4-(Trifluoromethyl)-2H-3,1-Benzoxazin-2-one
(DMP 266). Shelley R. Rabel, Michael B.
Maurin, Susan M. Rowe, and Munir A. Hussain.
Pharmaceutical Development and Technology 1 (1), 91-95 (1996).
- Applications
of Modulated Differential Scanning Calorimetry in Preformulation Studies. Shelley R. Rabel, Janan A. Jona, and Michael
B. Maurin. Journal of Pharmaceutical and
Biomedical Analysis, 21, pp. 339-345 (1999).
Student Group Advisement
- Co-Sponsor,
Student Affiliates of the American Chemical Society (SAACS)
Other Professional Experiences
-
2010-Present,
Member, Council on Undergraduate Research
-
2009-Present,
American Chemical Society
-
1990-Present,
Member, American Association of Pharmaceutical Chemists
-
Fourteen
years of Research and Development experience in the Pharmaceutical Industry(DuPont
Pharmaceuticals, Johnson and Johnson, Amgen)
Other
- Personal interests: Spending time with family, Sports (golf, skiing,
football, KU basketball), Travel
- Related Links:
rileyandrabel.com
